Lipocine Inc (LPCN) Stock Price, Quote & News

Company Profile

Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include LPCN 1111 (TLANDO XR), a next-generation long-acting oral product candidate for TRT; LPCN 1148, a novel prodrug of testosterone and testosterone...

Industry: Biotechnology

Sector: Healthcare

Phone: 801 994 7383

Fax: 801 994 7388

Website: www.lipocine.com

Address:

675 Arapeen Drive, Suite 202, Salt Lake City, United States

JarvisFlow Aug. 20 at 1:11 PM

HC Wainwright & Co. updates rating for Lipocine ( $LPCN ) to Buy, target set at 8.

1 · Reply

Tothemoonemoji Aug. 18 at 9:21 PM

$LPCN Added probably the last thousand today. At 36k now

2 · Reply

Tothemoonemoji Aug. 15 at 10:46 PM

$LPCN Added another thousand today, at 35k shares even. I hope my optimism isn't misplaced in that they actually strike a partnership and have positive study results.

0 · Reply

dbatech99 Aug. 14 at 7:26 PM

$LPCN this pos was born to just flat line. Quite possibly the worst investment I've ever made.

1 · Reply

agarfield Aug. 14 at 4:53 PM

$LPCN https://www.youtube.com/watch?app=desktop&v=2Nha1Zh63SA Looks like the FDA are taking a larger look into PPD and SSRIs specifically. I cannot help but wonder what this could mean for 1154. I would assume it helps since it is a neurosteroid and not an SSRI, but with a leadership more focused on pushing people off of antidepressants and promoting "wellness farms", I do worry a bit about if this affects LPCN's chances. Hopefully the science speaks for itself, but seems like that is less valuable than it once was.

1 · Reply

ZMhr Aug. 14 at 4:09 PM

$LPCN bananas

0 · Reply

Tothemoonemoji Aug. 14 at 3:30 PM

$LPCN Added another thousand this morning. At this rate I'll be catching up to @BioAB soon, lol

0 · Reply

Tothemoonemoji Aug. 14 at 2:32 AM

$LPCN Added another thousand today, at 32k shares.

1 · Reply

amazingcrwns Aug. 12 at 2:36 PM

$LPCN Minor update to the clinical trials website for the 1154 study. The only changes I see are the locations and status of the trial sites. There appear to be 9 sites that are recruiting now and 5 listed as not yet recruiting. https://clinicaltrials.gov/study/NCT06979544?term=Lipocine&rank=1

1 · Reply

brunoq14 Aug. 12 at 7:35 AM

$LPCN One fhing that makes me a little bit optimistic here is that Patel appears to think there is enough cash for 2401 as well as 1154. This gives me some confidence that there may at least be enough for 1154.

1 · Reply

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2025

Jun 26, 2025, 8:00 AM EDT - 2 months ago

Lipocine Announces First Patient Dosed in Phase 3 Clinical Trial for LPCN 1154 in Postpartum Depression

Jun 23, 2025, 8:00 AM EDT - 2 months ago

Lipocine to Host Virtual R&D Investor Event to Discuss LPCN 1154 (BRLIZIO™) as a Treatment for Postpartum Depression on July 9, 2025

Jun 9, 2025, 8:00 AM EDT - 2 months ago

Lipocine Announces Filing of New Drug Submission for TLANDO® in Canada

May 22, 2025, 8:00 AM EDT - 3 months ago

Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology

May 14, 2025, 8:00 AM EDT - 3 months ago

Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase

May 8, 2025, 8:00 AM EDT - 3 months ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025

May 6, 2025, 8:00 AM EDT - 3 months ago

Lipocine Announces License and Supply Agreement for TLANDO® in Brazil

Mar 26, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154

Mar 13, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2024

Mar 12, 2025, 8:00 AM EDT - 5 months ago

Lipocine Announces FDA Labeling Changes for Testosterone Products

Feb 6, 2025, 8:00 AM EST - 7 months ago

Lipocine Receives Updated Regulatory Guidance on LPCN 1154

Dec 17, 2024, 8:00 AM EST - 8 months ago

FDA Grants Fast Track Designation to Lipocine for LPCN 1148 as a Treatment for Sarcopenia in Patients with Decompensated Cirrhosis

Nov 18, 2024, 8:00 AM EST - 9 months ago

Lipocine Announces Publication and Discussion of LPCN 1148 Manuscript at The Liver Meeting 2024 Editor's Cut Session

Nov 7, 2024, 8:00 AM EST - 10 months ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2024

Oct 31, 2024, 8:00 AM EDT - 10 months ago

Lipocine Announces Distribution and License Agreement with SPC Korea to Commercialize TLANDO® in South Korea

Oct 10, 2024, 8:00 AM EDT - 11 months ago

Lipocine Announces Positive Oral Brexanolone Quantitative EEG Results

Oct 8, 2024, 8:00 AM EDT - 11 months ago

Lipocine Announces Supply and Distribution Agreement with Pharmalink to Commercialize TLANDO® in the Gulf Cooperation Council (GCC) Countries

Oct 2, 2024, 8:00 AM EDT - 11 months ago

Lipocine to Host Virtual KOL Event on LPCN 2401 for Improved Body Composition in Obesity Management on October 16, 2024

Sep 30, 2024, 8:00 AM EDT - 11 months ago

Lipocine to Present at H.C. Wainwright 8th Annual MASH Investor Conference

Sep 5, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Phase 2 Data on LPCN 2401 to be Presented at ObesityWeek®

Aug 27, 2024, 8:00 AM EDT - 1 year ago

Lipocine to Present at H.C. Wainwright 26th Annual Global Investment Conference

Aug 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2024

Jun 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces LPCN 1154 Meets Bioequivalence with IV Brexanolone in Pivotal Study

Jun 10, 2024, 8:00 AM EDT - 1 year ago

Lipocine Presents 52 Week Results from LPCN 1148 Phase 2 Study in Late Breaking Session at EASL Congress 2024

May 9, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2024

May 8, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024

May 1, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154

Apr 11, 2024, 7:00 AM EDT - 1 year ago

Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with Obesity

Mar 28, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with Cirrhosis

Mar 25, 2024, 8:00 AM EDT - 1 year ago

Lipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154

Mar 7, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Full Year Ended December 31, 2023

Mar 6, 2024, 8:00 AM EST - 1 year ago

Lipocine to Present at 36th Annual Roth Conference

Feb 6, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154

Feb 2, 2024, 8:00 AM EST - 1 year ago

Lipocine Announces Continued Commercialization of TLANDO® through Verity Pharmaceuticals

Jan 18, 2024, 8:00 AM EST - 1 year ago

Lipocine and Verity Pharma Enter into License Agreement for TLANDO® Franchise in the U.S. and Canada

Dec 19, 2023, 8:00 AM EST - 1 year ago

Lipocine to Present at Biotech Showcase 2024

Nov 13, 2023, 2:45 PM EST - 1 year ago

Lipocine Releases Late Breaking Presentation on LPCN 1148 Phase 2 Results at The Liver Meeting® 2023

Nov 8, 2023, 8:00 AM EST - 1 year ago

Lipocine Announces Financial Results for the Third Quarter Ended September 30, 2023

Nov 1, 2023, 8:00 AM EDT - 1 year ago

Lipocine to Present Clinical Data on LPCN 1148 at The Liver Meeting® 2023

Oct 26, 2023, 8:00 AM EDT - 1 year ago

Lipocine Completes Successful Meeting with FDA on LPCN 1154 in Postpartum Depression

Oct 23, 2023, 7:00 PM EDT - 1 year ago

Lipocine to Present at the H.C. Wainwright Annual NASH Investor Conference

Sep 19, 2023, 4:05 PM EDT - 2 years ago

Lipocine to Present at the Cantor Fitzgerald Global Healthcare Conference

Aug 10, 2023, 8:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the Second Quarter Ended June 30, 2023

Jul 27, 2023, 6:30 AM EDT - 2 years ago

LPCN 1148 Phase 2 Study Meets Primary Endpoint in Patients with Cirrhosis

Jun 14, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present at H.C. Wainwright Annual Neuropsychiatry Virtual Conference

Jun 7, 2023, 8:00 AM EDT - 2 years ago

Lipocine to Present LPCN 1148 and LPCN 1144 at the EASL Congress 2023

May 16, 2023, 7:00 AM EDT - 2 years ago

Positive Topline Clinical Results Support Streamlined Development Pathway for LPCN 1154, Lipocine's Oral Candidate for Rapid Relief of Depression

May 11, 2023, 6:00 AM EDT - 2 years ago

Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023

Apr 3, 2023, 8:00 AM EDT - 2 years ago

First Subject Dosed in the Clinical Bridge Study with Lipocine Depression Candidate, LPCN 1154

JarvisFlow Aug. 20 at 1:11 PM

HC Wainwright & Co. updates rating for Lipocine ( $LPCN ) to Buy, target set at 8.

1 · Reply

Tothemoonemoji Aug. 18 at 9:21 PM

$LPCN Added probably the last thousand today. At 36k now

2 · Reply

Tothemoonemoji Aug. 15 at 10:46 PM

$LPCN Added another thousand today, at 35k shares even. I hope my optimism isn't misplaced in that they actually strike a partnership and have positive study results.

0 · Reply

dbatech99 Aug. 14 at 7:26 PM

$LPCN this pos was born to just flat line. Quite possibly the worst investment I've ever made.

1 · Reply

agarfield Aug. 14 at 4:53 PM

1 · Reply

ZMhr Aug. 14 at 4:09 PM

$LPCN bananas

0 · Reply

Tothemoonemoji Aug. 14 at 3:30 PM

$LPCN Added another thousand this morning. At this rate I'll be catching up to @BioAB soon, lol

0 · Reply

Tothemoonemoji Aug. 14 at 2:32 AM

$LPCN Added another thousand today, at 32k shares.

1 · Reply

amazingcrwns Aug. 12 at 2:36 PM

1 · Reply

brunoq14 Aug. 12 at 7:35 AM

1 · Reply

Tothemoonemoji Aug. 11 at 5:53 PM

$LPCN At 31k at 3.50 average now

1 · Reply

HoHoHoHum Aug. 11 at 5:34 PM

$LPCN accummulating the dips

1 · Reply

Tothemoonemoji Aug. 11 at 4:27 PM

$LPCN Picked up another thousand shares here today at 1.95. How much lower do you all think we're going? I thought this MC was a joke before, but this is actually a joke already

2 · Reply

aah98a Aug. 7 at 8:32 PM

$LPCN Well, I have a big position in LPCN. The big issue is Cash on hand! They need a big influx of cash. If they can partner up with someone that will be ideal. Any partnership news and this stock will be up 100%++. If they try to raise the cash on their own it might be a long ride. Other possibility would be a buyout. Share price is so low any big Farma can scoop shares at a big discount and buy the company for cheap.

3 · Reply

Tothemoonemoji Aug. 7 at 2:55 PM

$LPCN What are we doing, going down to a dollar? This is priced like there's absolutely no pipeline, and we're smack in the middle of a phase 3. I don't get this action. If I wasn't tapped out I'd be averaging down even more.

2 · Reply

dbatech99 Aug. 7 at 1:16 PM

$LPCN come on you stinking POS... do something. Yawn.

0 · Reply

BioAB Aug. 7 at 2:25 AM

$LPCN missed this 😭😭😭😭

1 · Reply

RunningRobert1 Aug. 6 at 1:18 PM

$LPCN Lipocine Inc LPCN Q2 2025 Summary 06Aug2025 https://youtu.be/j85cVKcbbJM Earning Season is in full swing, and I know I covered this not to long ago but the report had enough new information to warrant a video. With Better sales from BIIB drug along with it seems a fairly certain time for data Q2 2026, we are moving in the right direction!

0 · Reply

premarketmaker Aug. 6 at 12:31 PM

$LPCN $1.06//AI

0 · Reply

d_risk Aug. 5 at 1:16 PM

$LPCN - Lipocine Inc. - 10Q - Updated Risk Factors LPCN’s 10-Q highlights key risks from uncertain FDA approval and commercialization of LPCN 1154, reliance on third-party suppliers, concentrated insider ownership, stock volatility, and ongoing significant operating losses from multiple drug programs. #Pharmaceuticals #OperatingLosses #StockVolatility #InsiderOwnership #Third-PartySuppliers #FDAApprovalRisk 🟢 Added 🟠 Removed https://d-risk.ai/LPCN/10-Q/2025-08-05

0 · Reply

BioAB Jul. 31 at 12:47 PM

$LPCN biogen is very positive about Zurzuvae. They call it a “sleeper” in their pipeline. And continues to grow.

1 · Reply

convicente Jul. 30 at 5:20 PM

$LPCN

0 · Reply

Market Cap	16.04M
Revenue (ttm)	11.20M
Net Income (ttm)	10,000.00
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.09%
Debt to Equity Ratio	0.00

Volume	1,597
Avg Vol	32,234
Day's Range	N/A - N/A
Shares Out	5.42M
Stochastic %K	64%
Beta	1.24
Analysts	Sell
Price Target	$7.38